Arbutus Biopharma Corporation ABUS
Updated: 19 Jun 2026
No signal published yet
We already track Arbutus Biopharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Arbutus Biopharma Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Arbutus Biopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
In May 2026, Arbutus reported a surge in first-quarter revenue to $179.1 million, primarily due to a patent litigation settlement with Moderna. The company also announced that its lead HBV candidate, imdusiran, has been granted FDA Fast Track designation.
What Firelda Watch includes for Arbutus Biopharma Corporation
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Arbutus Biopharma Corporation? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Arbutus Biopharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more